Immunitybio, Inc.
Clinical trials sponsored by Immunitybio, Inc., explained in plain language.
-
New drug takes on tough pancreatic cancer
Disease control CompletedThis study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
Immune cell therapy shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new immune cell therapy called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed by surgery. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The ther…
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC
-
Healthy donors get drug to supercharge immune cells
Knowledge-focused CompletedThis early study tested a drug called N-803 in 10 healthy volunteers to see if it could help collect and grow more natural killer cells from their blood. The main goal was to check safety and side effects. The study is already complete, but it does not test whether these cells ca…
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Knowledge-focused
Last updated Jun 23, 2026 22:18 UTC